About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a company based in United States founded in 1995. Lexicon Pharmaceuticals has raised $165 million across 13 funding rounds from investors including NEA, Bay City Capital and Military Health. The company has 103 employees as of December 31, 2024. Lexicon Pharmaceuticals offers products and services including Gene-based Therapies. Lexicon Pharmaceuticals operates in a competitive market with competitors including Metabolon, Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics and Maze Therapeutics, among others.
- Headquarter United States
- Employees 103 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lexicon Pharmaceuticals, Inc.
-
Annual Revenue
$31.08 M (USD)2481.48as on Dec 31, 2024
-
Net Profit
-$200.4 M (USD)-13.15as on Dec 31, 2024
-
EBITDA
-$184.28 M (USD)-7.64as on Dec 31, 2024
-
Total Equity Funding
$165 M (USD)
in 13 rounds
-
Latest Funding Round
$55.67 M (USD), Post-IPO
Feb 02, 2026
-
Investors
NEA
& 2 more
-
Employee Count
103
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol LXRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals offers a comprehensive portfolio of products and services, including Gene-based Therapies.
Develops medicines targeting neuropathic pain and cardiometabolic disorders using gene science.
People of Lexicon Pharmaceuticals
Unlock access to complete
Leadership Team
10 people
Product Management Team
6 people
Legal and Compliance
4 people
Human Resources and Administration
4 people
Software Development Team
3 people
Operations Team
3 people
Clinical Team
2 people
Finance and Accounting
2 people
Unlock access to complete
Funding Insights of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals has successfully raised a total of $165M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $55.67 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lexicon Pharmaceuticals
Lexicon Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include NEA, Bay City Capital and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life-sciences sectors are managed.
|
Locked | Locked | Locked | |
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Lexicon Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lexicon Pharmaceuticals
Investment portfolio details for Lexicon Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lexicon Pharmaceuticals
Detailed financials for Lexicon Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lexicon Pharmaceuticals Comparisons
Peer comparison for Lexicon Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics and Maze Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
Detailed competitors of Lexicon Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lexicon Pharmaceuticals
Complete news archive for Lexicon Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lexicon Pharmaceuticals
Lexicon Pharmaceuticals was founded in 1995 and raised its 1st funding round 3 years after it was founded.
Lexicon Pharmaceuticals is headquartered in United States.
Lexicon Pharmaceuticals is a funded company, having raised a total of $165M across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lexicon Pharmaceuticals is 103.
Annual revenue of Lexicon Pharmaceuticals is $31.08M as on Dec 31, 2024.
Lexicon Pharmaceuticals was founded in 1995 in the United States as a biopharmaceutical company. Gene trapping and targeting technologies are utilized to identify drug targets and create small molecule drugs. Focus areas include oncology, gastroenterology, immunology, metabolism, and ophthalmology. Operations center on research and development within the healthcare sector, with activities based primarily in the U.S.
Lexicon Pharmaceuticals's top competitors include Maze Therapeutics, Metabolon and Sana Biotechnology.
Lexicon Pharmaceuticals offers Gene-based Therapies.
Yes, Lexicon Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol LXRX.
Lexicon Pharmaceuticals has 3 investors. Key investors include NEA, Bay City Capital, and Military Health.
The ticker symbol of Lexicon Pharmaceuticals is LXRX on NASDAQ.